Parexel On Reimbursement Support, Federated Data Sharing, Diversity Through Communities

Interest in Cell & Gene Therapies Growing In India

Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.

Parexel's Kushal Gohil, Stephen Pyke, Sanjay Vyas
(L to R) Parexel Executives Kushal Gohil, Sanjay Vyas, Stephen Pyke • Source: Citeline/Scrip

Collaboration could be the mantra to drive significant gains in artificial intelligence (AI), clinical research and drug approvals, executives at Parexel International Corp., a major global provider of biopharma services including contract research, told Scrip in an interview that reveals insights across geographies and functional areas of expertise.

Chief strategy officer Kushal Gohil, based in the US, UK-based executive vice-president (EVP), Clinical Data and Digital Services, Stephen Pyke,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.